Abstract
Drugs treat diseases by blocking or modifying the functions of molecules such as proteins. Knowledge of the crystal structures of proteins is of tremendous help in designing effective drugs as the structures provide precise details of the mechanism of action and inhibition of the proteins at the atomic level. The impact of X-ray crystallography, by which the 3D structures are elucidated, on the efforts to combat diseases has been presented with a few examples.
Similar content being viewed by others
Suggested Reading
A Wlodawer and J Vondrasek, Inhibitors of HIV-1 protease: A major success of structure-assisted drug design, Annu. Rev. Biophys. Biomol. Struct., Vol.27, pp.249–84, 1998.
J F Riordan and M R Ehlers, K R Acharya and E D Sturrock, Ace revisited: a newtarget for structure-based drug design, Nat. Rev. Drug Discov., Vol.2, pp.891–902, 2003.
P J Loll, D Picot and R M Garavito, The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase, Nature struct. Biol., Vol.2, pp.637–643, 1995.
J N Varghese, WG Laver and P M Colman, Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 Å resolution, Nature, Vol.303, pp.35–40, 1983.
M N L Nalam and C A Schiffer, New approaches to HIV protease inhibitor drug design II: Testing the substrate envelope hypothesis to avoid drug resistance and discover robust inhibitors, Curr. Opin. HIV AIDS, Vol.3, pp.642–646, 2008.
Author information
Authors and Affiliations
Corresponding author
Additional information
K Suguna is a Professor at the Molecular Biophysics Unit, IISc, Bangalore. She is interested in determining the structures of biological macromolecules by X-ray crystallography to understand their structure-function relationships.
Rights and permissions
About this article
Cite this article
Suguna, K. Crystallography and drug design. Reson 19, 1093–1103 (2014). https://doi.org/10.1007/s12045-014-0135-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12045-014-0135-6